%A Hu Gengwei1, Zhang Ying2, Wu Zhihao3 %T Mechanism study and immunotherapy of immune checkpoint PD-1/PD-L1 %0 Journal Article %D 2019 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2019.02.005 %P 87-90 %V 46 %N 2 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10588.shtml} %8 2019-02-08 %X Programmed death ligand-1 (PD-L1) is highly expressed on most tumor cells, and it interacts with programmed death-1 (PD-1) on the surface of immune cells, which mainly inhibits T cell proliferation and plays an important role in tumor immune escape. The studies find that PD1/PDL1 pathway can promote tumor cell glycolysis and epithelialmesenchymal transition, and can induce PDL1 expression on macrophages and enhance immunosuppression in tumor microenvironment. Therefore, PD-1/PD-L1 is considered to be an important immunoassay point, and a series of antiPD-1 and PD-L1 antibodies, such as pembrolizumab, nivolumab, atezolizumab, durvalumab and avelumab, have clinically shown good effects. Further understanding of its mechanism may provide new ideas for the treatment of malignant tumors such as lung tumors.